A Pharmaceutico Analytical And Exploratory Trial Of Shila Sindoor In The Management Of Tamak Swasa (Bronchial Asthma)
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- change in subjective parameters
研究概览
简要总结
Summary:
Tamaka Swasa, which closely resembles bronchial asthma, is a leading cause of dyspnea (shortness of breath). Asthma is a major noncommunicable disease, affecting approximately 1.2-6.3% of adults globally, with around 300 million people suffering worldwide. This number has increased by 50% over the past decade. Conventional treatments, such as bronchodilators and corticosteroids, are effective but have long-term adverse effects, necessitating the need for alternative therapies.
This case study aims to explore the role of Shila Sindoor and Trikatu Churna in the management of Tamaka Swasa (Bronchial Asthma). The study seeks to validate their effectiveness as an Ayurvedic alternative for asthma treatment.
In both Ayurveda and Modern Medicine, Swasa refers to difficulty in breathing or asthma, caused by both host factors (Nija Hetu—Dosha Dushti and Aam) and environmental factors (Aagantuja Hetus—dust, smoke, wind, etc.). According to Sushruta, Swasa occurs when Vata (the vital force) becomes vitiated, obstructing the respiratory passage due to Kapha, leading to difficulty in breathing. Tamaka Swasa is classified as a Vata-Kapha type of Swasa and corresponds closely to bronchial asthma in modern medicine. Asthma is a chronic inflammatory disease of the airways, characterized by episodic dyspnea, chest tightness, wheezing, and coughing, especially at night or early morning.
Need for the Study:
To reduce reliance on steroids for asthma control by exploring Ayurvedic formulations as alternative treatments.
To evaluate the potential of Shila Sindoor and Trikatu Churna in managing Tamaka Swasa, as clinical research on this combination is currently lacking.
This study aims to provide a safer, alternative approach to asthma management, addressing the growing need for more sustainable treatments.
研究设计
- 研究类型
- Interventional
- 分配方式
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Age between 18-60 years irrespective of sex.
- •Patients having cardinal sign and symptoms as in Ayurvedic classics and contemporary medicine.
- •Night symptoms more than twice per month but less than once a week.
- •Patients who meet reversibility criteria.
- •FEV1 is grater then 80 pracent of the predicted value.
- •Diagnosed mild and moderate cases of asthma (GINA) without any co morbidity.
排除标准
- •Patients having other associated diseases like LVFURTI, Bronchiectasiscases of tuberculosis, IL.D
- •Patients having major systemic illness.
- •Patients having Renal and Hepatic disease.
- •Patients with HIV Positive.
- •Pregnant and lactating mothers should be excluded.
- •Patients without written consent form.
结局指标
主要结局
change in subjective parameters
时间窗: 30 days
次要结局
- Improvememt in quality of life of patient(30 days)
研究者
Dr Manoj Barupal
PGIA JODHPUR